Register Login
Register to leave comments
  • News bot Aug. 13, 2026, 12:40 p.m.

    📋 FATE THERAPEUTICS INC (FATE) - Financial Results

    Filing Date: 2026-08-13

    Accepted: 2026-08-13 08:31:59

    Event Type: Financial Results

    Event Details:

    FATE THERAPEUTICS INC (FATE) Reports the reporting period Financial Results FATE THERAPEUTICS INC (FATE) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 381
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 32429
      • targeting the B-cell lineage marker CD19 and a second CAR targeting the immune activation marker CD38, which is often found on aberrant T, NK and B cells. FT839 is a 13-point edited CAR T cell and the second program to incorporate the Company’s Sword & Shield™ technology. The FDA cleared the IND application for FT839 in July 2026
      • targeting off-the-shelf CAR T-cell product candidate into a Phase 1/2 basket trial in autoimmune disease Preliminary clinical data in SSc presented at the ISSCR 2026
      • targeting major histocompatibility complex class I chain-related proteins A (MICA) and B (MICB). The expression of MICA/B cell-surface proteins is induced by cellular stress or malignant transformation and is detectable across many types of cancer cells with limited expression on healthy tissue. FT836 is the Company’s first product candidate to incorporate the novel Sword & Shield™ technology, which utilizes the Company’s novel alloimmune defense receptor (ADR) alongside CD58 knockout, to both target and evade host alloreactive immune cells for a comprehensive strategy to avoid the need for conditioning chemotherapy. In January 2025

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expenses Loss From Operations 36.97K 64.13K $-27.17K -42.36%
    Other Income Expense Interest Income 2.92K 3.42K $-501.00 -14.64%
    Other Income Expense Net Loss 34.07K 61.37K $-27.30K -44.49%
    Other Comprehensive Loss Net Loss Per Share 0.29 0.51 $-0.22 -43.14%
    Current Assets Prepaid Expenses Other Current Assets 3.48K 4.13K $-651.00 -15.76%
    Current Assets Operating Lease Right Of Use Assets 40.55K 41.61K $-1.05K -2.54%
    Revenue 2.08K 1.91K $175.00 +9.18%
    Loss from Operations 31.13K 36.97K $-5.83K -15.78%
    Interest Income 1.55K 2.92K $-1.37K -46.76%
    Other Income, Net 975.00 2.90K $-1.92K -66.36%
    Net Loss 30.16K 34.07K $-3.91K -11.48%
    Prepaid Expenses and Other Current Assets 3.48K 4.13K $-651.00 -15.76%
    Accounts Payable 18.16K 22.68K $-4.52K -19.92%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: FATE THERAPEUTICS INC
    • Ticker Symbol: FATE

Search

News categories